Edobacomab, with the CAS number 141410-98-2, is a monoclonal antibody that has been investigated for its potential therapeutic applications, particularly in the context of autoimmune diseases and certain types of cancer. As a humanized IgG1 antibody, it is designed to target specific antigens, thereby modulating immune responses. The mechanism of action typically involves binding to a particular target on immune cells or pathogens, which can lead to the inhibition of inflammatory processes or the enhancement of immune-mediated tumor cell destruction. Edobacomab's structure allows for a prolonged half-life in circulation, which is a common characteristic of monoclonal antibodies, facilitating less frequent dosing regimens. Its development has been part of ongoing research to improve treatment options for patients with challenging medical conditions. As with many biologics, the safety and efficacy profile of Edobacomab is subject to rigorous clinical testing to ensure it meets regulatory standards before it can be widely used in clinical practice.

Edobacomab

141410-98-2: Edobacomab, with the CAS number 141410-98-2, is a monoclonal antibody that has been investigated for its potential therapeutic applications, particularly in the context of autoimmune diseases and certain types of cancer. As a humanized IgG1 antibody, it is designed to target specific antigens, thereby modulating immune responses. The mechanism of action typically involves binding to a particular target on immune cells or pathogens, which can lead to the inhibition of inflammatory processes or the enhancement of immune-mediated tumor cell destruction. Edobacomab's structure allows for a prolonged half-life in circulation, which is a common characteristic of monoclonal antibodies, facilitating less frequent dosing regimens. Its development has been part of ongoing research to improve treatment options for patients with challenging medical conditions. As with many biologics, the safety and efficacy profile of Edobacomab is subject to rigorous clinical testing to ensure it meets regulatory standards before it can be widely used in clinical practice.

<p>Mouse monoclonal IgM antibody to gram negative bacterial endotoxin</p>

Edobacomab (E5), a monoclonal IgM antibody targeting endotoxin, is utilized in the study of sepsis stemming from Gram-negative bacterial infections [1].

CAS 141410-98-2

Edobacomab

Edobacomab

Ref: 3D-CLA1095

Edobacomab

Ref: TM-T82505